Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-17043 and PG043 in open-angle glaucoma and ocular hypertension
NCT06441643Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AR-17043 in open-angle glaucoma (OAG) and ocular hypertension (10 arms), sponsored by Alcon Inc. Primary endpoint: Mean diurnal intraocular pressure at 29 days. Started Sep 2024; status: completed.
02
Drugs
AR-17043
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06441643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441643.